Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study

Table 2

(a) Standardised incidence ratios for cancers in all sites in the study population

Characteristic	Observed	Expected	SIR	95% CI
All	41	37.5	1.09	0.81 to 1.49
Non-NMSC	34	35.4	0.96	0.69 to 1.34
Sex
Male	29	22.9	1.27	0.88 to 1.83
Female	12	14.6	0.82	0.47 to 1.44
Follow-up period
0-1 year	3	4.3	0.70	0.22 to 2.16
1–5 years	22	14.4	1.53	1.01 to 2.32
5–10 years	11	11.1	0.99	0.55 to 1.78
>10 years	5	7.6	0.66	0.27 to 1.57
Transplantation
Yes	7	3.3	2.12	1.01 to 4.44
No	34	34.2	0.99	0.71 to 1.39
ANCA serology
C-ANCA/PR3-ANCA	24	20.6	1.17	0.78 to 1.74
P-ANCA/MPO-ANCA	17	16.9	1.01	0.63 to 1.62
Study period
1988–2002	26	22.7	1.14	0.78–1.68
2003–2012	15	14.8	1.02	0.61–1.68

SIR, standardised incidence ratio; 95% CI, 95% confidence interval; NMSC, nonmelanoma skin cancer; C-ANCA, cytoplasmic ANCA; PR3-ANCA, proteinase 3 ANCA; P-ANCA, perinuclear ANCA; MPO-ANCA, myeloperoxidase ANCA.

(b) Standardised incidence ratios for the most common organ-specific cancers in the study population

Organs	Observed	Expected	SIR	95% CI
NMSC	7	2.1	3.40	1.62 to 7.14
Hematologic	4	1.1	3.52	1.32 to 9.37
Lung	7	4.0	1.73	0.83 to 3.63
Colon	2	1.2	1.73	0.43 to 6.93
Urothelium	3	2.0	1.48	0.47 to 4.59
Prostate	5	7.0	0.72	0.30 to 1.73
NHL	1	1.2	0.86	0.12 to 6.12

SIR, standardised incidence ratio; 95% CI, 95% confidence interval; NMSC, nonmelanoma skin cancer; NHL, non-Hodgkin lymphoma.